Skip to main content

Table 1 Predictive factors for PD-1/PD-L1 blockade therapy

From: Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Tumor type Agent Predictive factor Reference
Non-small cell lung cancer Atezolizumab PD-L1 [68]
Multiple cancers Pembrolizumab PD-L1 [69]
Colorectal cancer Nivolumab MMR / MSI [70]
Urothelial carcinoma Atezolizumab TMB [71]
Urothelial carcinoma Atezolizumab TMB [72]
Urothelial cancer Atezolizumab TMB [73]
Melanoma Anti-PD-1 therapy Gut microbiome [74]
Melanoma Anti-PD-1 therapy Gut microbiome [75]
Melanoma Anti-PD-1 therapy Gut microbiome [61]
  1. MMR: mismatch repair; MSI: microsatellite instability; TMB: tumor mutation burden